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ABSTRACT 
Objective: Two simple, accurate and reproducible spectrophotometric methods have been developed and validated for simultaneous estimation of 
metformin (MET) and pioglitazone (PIO) in bulk and tablet dosage forms. 
Methods: (1) Area under curve method (Area calculation): The proposed area under the curve method involves measurement of area at selected 
wavelength ranges. Two wavelength ranges were selected 228-238 nm and 265-275 nm for estimation of MET and PIO respectively. (2) Dual 
wavelength method: In the dual-wavelength method, two wavelengths were selected for each drug in a way so that the difference in absorbance is 
zero for another drug. PIO shows equal absorbance at 235 and 266 nm, where the difference in absorbance was measured for determination of 
MET. Similarly, the difference in absorbance at 216 and 241.5 nm was measured for determination of MET. 
Results: Linearity range for MET and PIO is 2-10 μg/ml and 10-50 μg/ml at respective selected wavelengths. Accuracy and precision studies were 
carried out and results were satisfactory. The proposed methods have been validated as per ICH guidelines and successfully applied to the 
estimation of MET and PIO in their combined tablet dosage form. 
Conclusion: The developed methods are simple, precise, rugged and economical. The utility of the methods has been demonstrated by analysis of 
commercially available formulations.  
Keywords: Metformin, Pioglitazone, Area under curve method, Dual wavelength method 
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INTRODUCTION 
Diabetes mellitus, commonly referred to as diabetes, is a group 
of metabolic diseases in which there are high blood sugar levels over 
a prolonged period. Globally, diabetes is likely to be the fourth 
leading cause of death [1]. Approximately 90% of people with 
diabetes have type 2 diabetes. It usually begins as insulin resistance, 
a disorder in which the cells do not use insulin properly. As the need 
for insulin rises; the pancreas gradually loses its ability to produce 
insulin. Type II diabetes is associated with older age, obesity, family 
history of gestational diabetes, impaired glucose metabolism, 
physical inactivity and race/ethnicity [2]. If the glycemic target level 
is not achieved with one oral agent alone, combination oral and/or 
insulin therapy is recommended [3, 4]. Combination oral therapy 
becomes an obvious choice when glycemic control is not achieved 
with conventional monotherapy [5]. The advantages of oral dose 
combinations as compared to their components which are taken 
alone are lower cost and better patient compliance [6, 7]. 
Combination therapy has been shown to have achieved greater 
blood glucose lowering than non-combination therapy because 
different classes have different and complementary mechanisms of 
action. Therefore, it is more logical to add another drug than replace 
the existing drug. The rapid introduction of combination therapy 
with two or three complementary oral antidiabetics helps in 
targeting the dual effect and also reduced adverse effects [8]. 
Pioglitazone (PIO) is chemically [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) 
ethoxy] phenyl] methyl]-2, 4-] thiazolidinedione [9] [fig. 1 (a)]. It is an 
orally-active thiazolidinedione with antidiabetic properties and 
potential antineoplastic activity. PIO activates peroxisome 
proliferator-activated receptor gamma (PPAR-gamma), a ligand-
activated transcription factor, thereby inducing cell differentiation and 
inhibiting cell growth and angiogenesis. This agent also modulates the 
transcription of insulin-responsive genes, inhibits macrophage and 
monocyte activation, and stimulates adipocyte differentiation [10]. 
Metformin (MET) is chemically (N, N-dimethyl imido dicarbon imidic 
diamide) [11] [fig. 1 (a)]. MET is a member of the biguanide class of 
oral antihyperglycemics improves glucose tolerance in patients with 
type 2 diabetes, lowering both basal and postprandial plasma glucose. 
MET decreases hepatic glucose production, decreases intestinal 
absorption of glucose and improves insulin sensitivity by increasing 
peripheral glucose uptake and utilization [12]. 
 
 
Fig. 1: Chemical structures of (a) MET and (b) PIO 
 
The review of literature stated that various analytical methods 
involving spectrophotometry [13], HPLC [14], and HPTLC [15] have 
been reported for PIO in a single form and in combination with other 
drugs. Several analytical methods have been reported for MET in a 
single form and in combination with other drugs, including 
spectrophotometry [16], HPLC [17-19], HPTLC [20], LC-MS [21] 
methods.  
For the simultaneous estimation of MET and PIO in tablets, vierodt’s 
method and an absorption correction method by Sujana et al. [13], a 
simultaneous equation method by Rathod et al. [22] and another 
two methods; derivative spectrophotometry and Q-analysis by 
Goswami et al. have been reported [23]. 
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However, no references have been found for simultaneous 
estimation of MET and PIO in their combined tablet dosage form by 
the area under the curve (AUC) and dual wavelength (DW) method. 
Both these methods are simple, accurate and precise for estimation 
of MET and PIO in combined tablet dosage form and do not require 
any complicated sample treatment like heating or organic solvent 
extraction and costly instrument like HPLC.  
AUC method offers an efficient method which involves measurement 
of area under the curve at two sampling wavelength ranges for the 
estimation of MET and PIO. DW method is another easy and efficient 
method for analyzing a component in the presence of an interfering 
component. For elimination of interferences, dual analytical 
wavelengths were selected in a way to make the absorbance 
difference zero for one drug while it is directly proportional to the 
concentration of the other drug ( a component of interest).  
MATERIALS AND METHODS 
Instrumentation 
UV/Visible spectrophotometer: SICAN-2301, Inkarp instruments Pvt Ltd.  
Analytical balance: Sartorius BSA223S-CW  
Magnetic stirrer: REMI 1MLH, Remi laboratories limited. 
Reagents and chemicals 
MET: Gift sample from covalent laboratories Pvt. Ltd., Hyderabad.  
PIO: Gift sample from Neuland laboratories Ltd., Hyderabad.  
Formulation of MET and PIO: moxicip FC, Cipla limited and mahacef, 
Mankind Ltd.  
Solvent: Methanol analytical grade, Merck.  
Preparation of stock standard solutions 
The stock solutions of MET and PIO were prepared separately by 
dissolving accurately 50 mg of the drug in methanol and the volume 
was made up to 50 ml with methanol to prepare standard stock 
solution (1 mg/ml). 
Preparation of sample solutions 
The stock standard solutions (1 mg/ml) of MET and PIO were further 
diluted to obtain the final concentration 2, 4, 6, 8, 10, 12 μg/ml and 10, 
20, 30, 40 and 50 μg/ml respectively. Both the solutions were scanned 
in the spectrum mode from 200 nm to 400 nm. 
Method 1: Area under curve method 
For the selection of the analytical wavelength solutions of MET (6 
μg/ml) and PIO (30 μg/ml) were prepared separately by 
appropriate dissolution from stock standard solutions and scanned 
between 200 to 400 nm using methanol as blank. From the overlain 
spectra (Fig.3) of both drugs the AUC was determined at both the 
selected analytical wavelength ranges. 
  
 
Fig. 2: Overlay of MET (6 μg/ml) and PIO (30 μg/ml) 
 
 
Fig. 3: MET (6 μg/ml) 
 
 
Fig. 4: PIO (30 μg/ml) 
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Wavelength range selected were 228-238 nm for determination of 
AUC of MET and 265-275 nm for determination of AUC of PIO. The 
Calibration curve was prepared in the concentration range of 2-10 
μg/ml for MET at 228 to 238 nm. The Calibration curve was 
prepared in the concentration range of 10-50 μg/ml for PIO at 265 
to 275 nm. The ‘X’ value is the ratio of AUC at selected wavelength 
ranges (228-238 nm and 265-275 nm) with a concentration of a 
component in μg/ml. The concentration of each drug was calculated 
using following “Cramer’s and Matrix rule” equation:  
CMET = (A2ay1 −  A1ay2) (ax2ay1 −  ax1ay2⁄ )-(1) 
CPIO = (A1ax2 −  A2ax1) (ax2ay1 −  ax1ay2)⁄ -(2) 
Where, 
CMET = Concentrations of MET,  
CPIO = Concentrations of PIO, 
A1 = Area at 228-238 nm, 
A2 = Area at 265-275 nm, 
ax1 = X value of MET at 228-238 nm, 
ax2 = X value of MET at 265-275 nm, 
ay1 = X value of PIO at 228-238 nm, 
ay2 = X value of PIO at 265-275 nm. 
Method 2: Dual wavelength method 
The principle of DW method is “the absorbance difference between 
two points on the mixture spectra is directly proportional to the 
concentration of the component of interest”. 
The pre-requisite for the DW method is the selection of two such 
wavelengths where the interfering component shows the same 
absorbance whereas the component of interest shows a significant 
difference in absorbance with concentration. 
The overlain spectrum of PIO and MET suggested that a DW 
spectrophotometric method is a suitable method for simultaneous 
determination of MET and PIO.  
The wavelengths selected for determination of MET were 235 nm 
and 266 nm, where the absorbance difference was zero for PIO. The 
wavelengths selected for determination of PIO were 216 nm and 
241.5 nm where the absorbance difference was zero for MET. 
The calibration curve was prepared in the concentration range of 2-
10 μg/ml for MET at 235 nm to 266 nm. The calibration curve was 
prepared in the concentration range of 10-50 μg/ml for PIO at 216 
nm to 241.5 nm. 
 
 
Fig. 5: Overlay of MET (6 μg/ml) and PIO (30 μg/ml) 
 
Assay of tablet formulation 
20 tablets each of MET and PIO were weighed and average weight 
noted. Then the tablets were crushed and powdered, and tablet 
powder equivalent to 500 mg of MET and 5 mg of PIO respectively was 
weighed and dissolved in 100 ml methanol. The solution was then 
filtered through Whatmann filter paper No.41 and diluted further to 
obtain a final concentration of 6 μg/ml of MET and 30 μg/ml of PIO. 
The sample solutions were analyzed as per the procedure for mixed 
standards. The concentrations of each drug in sample solutions were 
calculated using equations (i) and (ii) for the AUC method. In the DW 
method, the responses of the sample solution were measured at 216 
nm, 235 nm, 241.5 nm and 266 nm for quantification of MET and PIO. 
The amounts of the MET and PIO present in the sample solution were 
calculated by fitting the responses into the regression equation for 
MET and PIO in the proposed method. 
Method validation 
The proposed methods were validated according to ICH Q2B 
guidelines for validation of analytical procedures in order to 
determine the linearity, sensitivity, precision and accuracy, etc. of 
the analytes [24]. 
Accuracy 
Accuracy may often be expressed as % Recovery by the assay of 
known, added amount of analyte. It is a measure of the exactness of 
the analytical method. Recovery studies were carried out for both 
the methods by spiking standard drug in the powdered formulations 
80%, 100%, 120% amount of each dosage content as per ICH 
guidelines. The recovery study was performed three times at each 
level for both methods. 
 
Table 1: Statistical validation of recovery studies 
Level of % recovery Methods %Recovery* % RSD* 
MET PIO MET PIO 
80% AUC 101.49 100.63 0.953 0.972 
DW 99.938 100.68 1.454 0.643 
100% AUC 100.93 102.28 1.677 1.508 
DW 99.883 100.89 1.293 0.477 
120% AUC 100.76 101.92 0.894 1.708 
DW 99.579 100.58 1.039 1.083 
*Average of three estimations at each level of recovery 
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The reproducibility of the proposed method was determined by 
performing tablet assay on the same day (Intra-day assay precision) 
and on three different days (Inter-day precision).  
Inter-day precision 
Mixed standard solutions containing 4, 6, 8 μg/ml MET and 20, 30, 
40 μg/ml of PIO were analyzed on three consecutive days. The 
results were reported in terms of %RSD by both the methods. 
 
Table 2: Statistical validation of Inter-day precision 
Drugs Methods %Amount found±SD* %RSD* 
MET AUC 101.14±0.08 1.41 
DW 100.91±0.09 1.55 
PIO AUC 100.45±0.10 0.41 
DW 99.96±0.21 0.74 
*Average of six estimations 
 
Table 3: Statistical validation of intra-day precision 
Drugs Methods % Amount found±SD* % RSD* 
MET AUC 101.74±0.06 1.07 
DW 101.18±0.08 1.37 
PIO AUC 100.38±0.08 0.25 
DW 100.33±0.08 0.33 
*Average of six estimations 
 
Table 4: Optical characteristics of MET and PIO 
Parameters AUC method DW method 
 MET PIO MET PIO 
Wavelength Range 228-238 nm 265-275 nm 235-266 nm 216-241.5 nm 
Concentration Range 2-12 µg/ml 10-50 µg/ml 2-12 µg/ml 10-50 µg/ml 
Regression Equation y = 0.7514x-0.6636 y = 0.1541x-0.2398 y = 0.0758x-0.03 y = 0.0153x-0.0011 
Slope 0.7514 0.1541 0.0758 0.0153 
Intercept -0.6636 -0.2398 0.03 0.0011 
Correlation Coefficient 0.9986 0.9969 0.9945 0.9933 
LOD (µg/ml) 0.252 0.266 0.251 0.234 
LOQ(µg/ml) 0.763 0.806 0.76 0.71 
LOD=Limit of Detection, LOQ=Limit of Quantification 
 
Intra-day precision 
Mixed standard solutions containing 4, 6, 8 μg/ml MET and 20, 30, 
40 μg/ml of PIO were analyzed at different time intervals (morning, 
afternoon and evening) on the same day. The results were reported 
in terms of %RSD by both the methods. 
Linearity 
The measurement of linearity was evaluated by analyzing different 
concentrations of the standard solution of MET and PIO. For both the 
methods, the Beer law was obeyed in the concentration range 2-10 
μg/ml and 10-50 μg/ml for MET and PIO respectively. The 
absorbance was plotted against the corresponding concentrations to 
obtain the calibration plots. 
Limit of detection and limit of quantitation 
Limit of detection is the lowest amount of analyte in a sample which 
can be detected, but not necessarily quantitated as an exact value 
and limit of quantitation is the lowest amount of analyte in a sample 
which can be quantitatively determined with suitable precision and 
accuracy. The limit of detection (LOD) and the limit of quantification 
(LOQ) of the drug was derived by calculating the signal-to-noise 
ratio (S/N) using the following equations designated by 









Where, σ = the standard deviation of the response and S = slope of 
the calibration curve. The LOD and LOQ were separately determined 
based on the calibration curve. 
RESULTS AND DISCUSSION  
In the AUC method solutions of PIO and MET were scanned 
separately between 200 to 400 nm using methanol as blank. 
Maximum absorbance is obtained at 268 nm for PIO and 232 nm for 
MET. Two wavelength ranges were selected 265-275 nm and 228-
238 nm for estimation of PIO and MET respectively (fig. 3 and fig. 4). 
Linear regression equations for PIO and MET were found to be y = 
0.1541x-0.2398 and y = 0.7514x-0.6636 respectively. Linearity data 
as summarized in table 4 proves that the method is linear and is 
within specified criteria of ICH guidelines. 
The utility of dual wavelength data processing program is its ability 
to calculate the unknown concentration of the component of interest 
in a mixture containing an interfering component. For elimination of 
the effects of interfering components, two specific wavelengths were 
chosen 235 nm and 266 nm for the determination of MET, where the 
absorbance difference was zero for PIO and 216 nm and 241.5 nm 
for the determination of PIO where absorbance difference was zero 
for MET. Absorbance difference was determined between 
wavelengths 266-235 nm and 241.5-216 nm and calibration curves 
were plotted between absorbance difference values and 
concentration of the drug.  
Linearity range for MET and PIO is 2-10 μg/ml and 10-50 μg/ml at 
respective selected wavelengths. The coefficient of correlation for 
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MET at the range 228-238 nm and PIO at the range 265-275 nm is 
0.9996 and 0.9999 respectively, for AUC method and 0.9997 and 
0.9999 for MET at 235-266 nm and PIO at 216-241.5 nm 
respectively for DW method (table 4). MET and PIO shows limit of 
detection 0.252 μg/ml and 0.266 μg/ml for AUC method and 0.251 
μg/ml and 0.234 μg/ml for DW method and limit of quantitation 
0.763 μg/ml and 0.806 μg/ml for AUC method and 0.761 μg/ml and 
0.710 μg/ml for DW method respectively (table 4). In both Intra and 
inter-day precision study for both shows %RSD are not more than 
2.0%, which indicates good repeatability and intermediate precision 
(table 2 and 3). Mean % recovery studies results ranged from 
100.76% to 101.49% for MET and 100.63% to 102.28% for PIO in 
AUC method and 99.58% to 99.94% for MET and 100.58% to 
100.89% for PIO in DW method with % RSD values, not more than 
2.0%, which indicates that any small change in the drug 
concentration in the solution could be accurately determined by the 
proposed methods (table 1). The % assay was found to be 99.66% to 
100.41 % for MET and 99.53 to 99.73 for PIO in AUC method and 
99.48 to 99.64 for MET and 99.07 to 99.53 for PIO in DW method 
with % RSD values, not more than 2.0% indicating the precision of 
this method (table 5). No interference was observed from the 
pharmaceutical adjuvants/excipients. 
  
Table 5: Statistical validation of tablet formulation 
Brand Drug Method Amount present (mg) % Amount found SD* % RSD* 
Diavista-M (Dr. Reddy's) MET AUC 500 100.41 0.51 0.10 
DW 500 99.64 0.11 0.02 
PIO AUC 15 99.73 0.06 0.39 
DW 15 99.53 0.02 0.02 
Exermet-P (Cipla) MET AUC 500 99.66 1.03 0.21 
DW 500 99.48 0.55 0.11 
PIO AUC 15 99.53 0.19 1.30 
DW 15 99.07 0.20 1.35 
 
CONCLUSION  
Both of the proposed Spectrophotometric methods are simple, rapid, 
accurate, precise, and economical and validated in terms of linearity, 
accuracy, precision and reproducibility as per ICH guidelines. These 
two methods can be successfully used for simultaneous estimation 
of MET and PIO in pure and marketed tablet dosage form. These 
proposed two methods can also be used for routine quality-control 
analysis of these drugs in pure and its pharmaceutical dosage forms. 
ABBREVIATION 
AUC-Area under the curve, DW-Dual Wavelength, MET-Metformin, PIO-
Pioglitazone, ICH-International Conference on Harmonization, HPLC-
High performance liquid chromatography, HPTLC-High performance 
thin layer chromatography, LC-MS-Liquid chromatography-mass 
spectrophotometer, μg-microgram (s), mg-milligram (s), nm-nanometer 
(s), %R. SD-Percentage Relative Standard Deviation, SD-Standard 
deviation, LOD-Limit of detection, LOQ-Limit of Quantitation. 
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